Five‐Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study
Jerry R. Mendell, Zarife Sahenk, Linda P. Lowes, Megan A. Iammarino, Lindsay N. Alfano, Craig M. McDonald, James E. Signorovitch, Jim Jin, Jing Li, Stefanie Mason, Louise R. Rodino‐Klapac · 2026
Read Five‐Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study by Jerry R. Mendell, Zarife Sahenk, Linda P. Lowes, Megan A. Iammarino, Lindsay N. Alfano, Craig M. McDonald, James E. Signorovitch, Jim Jin, Jing Li, Stefanie Mason, Louise R. Rodino‐Klapac (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13332556.txt.
Description
Jerry R. Mendell and colleagues report 2026 five-year results for delandistrogene moxeparvovec in Duchenne muscular dystrophy. The therapy is a single intravenous dose of a virus-vector gene treatment tested in a phase 1/2a open-label trial. Four walking boys aged four to under eight at entry received the dose, and safety plus function were tracked for five years. Function measures included the North Star Ambulatory Assessment score, time to rise from the floor, and ten-metre walk or run time.
No new safety signals emerged over five years. Post hoc analyses compared treated boys with propensity-weighted external controls and with natural history predictions to place function in context. The tiny cohort limits firm claims, yet five-year follow-up is rare and valuable in this field. Families and clinicians gain a longer view of safety and function after a one-time gene therapy for Duchenne.
Catalog record
| CREATOR | Jerry R. Mendell, Zarife Sahenk, Linda P. Lowes, Megan A. Iammarino, Lindsay N. Alfano, Craig M. McDonald, James E. Signorovitch, Jim Jin, Jing Li, Stefanie Mason, Louise R. Rodino‐Klapac |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |